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Abstract
Disseminated intravascular coagulation (DIC) is a disorder characterized by both acute generalized,
widespread activation of coagulation, which results in thrombotic complications due to the
intravascular formation of fibrin, and diffuse hemorrhages, due to the consumption of platelets and
coagulation factors. Systemic activation of coagulation may occur in a variety of disorders, including
sepsis, severe infections, malignancies, obstetric or vascular disorders, and severe toxic or
immunological reactions.
In this review, we briefly report the present knowledge about the pathophysiology and diagnosis
of DIC. Particular attention is also given to the current standard and experimental therapies of
overt DIC.
Background
Disseminated intravascular coagulation (DIC) is a disor-
der characterized by massive systemic intravascular activa-
tion of coagulation, leading to widespread deposition of
fibrin in the circulation which can compromise the blood
supply to various organs, thus contributing to multiple
organ failure. At the same time, the consumption of plate-
lets and coagulation proteins resulting from the ongoing
coagulation may induce severe bleeding[1-6]. However,
DIC is not a disease itself but is always secondary to an
underlying disorder [7,8]. In fact, a variety of clinical con-
ditions may cause systemic activation of coagulation.
Table 1 lists the diseases most frequently associated with
DIC. Bacterial infections, in particular septicemia, are the
most common clinical conditions associated with DIC.
There is no difference in the incidence of DIC in patients
with Gram-negative or Gram-positive sepsis. Systemic
infections by other micro-organisms, such as viruses and
parasites, may also lead to DIC. The generalized activation
of coagulation occurring in these cases is mediated by cell
membrane components of micro-organisms (lipopolysac-
charide or endotoxin) or bacterial exotoxins, such as sta-
phylococcal α hemolysin, which cause a generalized
inflammatory response through the activation of pro-
inflammatory cytokines [9-13]. Severe trauma and burns
are other conditions frequently associated with DIC
[14,15]. Both solid and hematologic cancers may be asso-
ciated with DIC, which can complicate up to 15 percent of
cases of metastasized tumors or acute leukemia [16-18].
DIC is also a frequent complication (occurring in more
than 50 percent of cases) of some obstetric conditions
such as abruptio placentae and amniotic fluid embolism
[19,20]. Finally, selected vascular disorders, such as giant
hemangiomas and large aortic aneurysms, and severe
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hemolytic transfusion reactions and transplant rejection)
can be associated with DIC [2,8].
In the following sections we briefly discuss the current
knowledge on the pathogenesis, diagnosis and treatment
of DIC.
Pathogenesis of DIC
Most of the recent advances in our understanding ofthe
pathogenesis of DIC are derived from studies in animal
models and humans with severe sepsis [6]. These studies
have demonstrated that the systemic formation of fibrin
observed in this setting is the result of the simultaneous
coexistence of four different mechanisms: increased
thrombin generation, a suppression of the physiologic
anticoagulant pathways, impaired fibrinolysis and activa-
tion of the inflammatory pathway [1,8,21].
The systemic generation of thrombin has been shown to
be mediated predominantlyby the extrinsic (factor VIIa)
pathway. In fact, while the abrogation of the tissue factor/
factor VIIa pathway resulted in complete inhibition of
thrombin generation in experimental animal models of
endotoxemia, the inhibition of the contact system did not
prevent systemic activation of coagulation [22,23].
Impaired function of physiological anticoagulant path-
ways may amplify thrombin generation and contribute to
fibrin formation [24]. Plasma levels of antithrombin are
markedly reduced in septic patients as a result of a combi-
nation of increased consumption by the ongoing forma-
tion of thrombin, enzyme degradation by elastase
released from activated neutrophils, impaired synthesis
due to liver failure and vascular capillary leakage [6,7,25].
Likewise, there may be significant depression of the pro-
tein C system, caused by enhanced consumption,
impaired liver synthesis, vascular leakage and a down-reg-
ulation of thrombomodulin expression on endothelial
cells by pro-inflammatory cytokines, such as tumor necro-
sis factor (TNF)-α and interleukin(IL)-1β [26-28]. Moreo-
ver, the evidence that administration of recombinant
tissue factor pathway inhibitor (TFPI) results in complete
inhibition of endotoxin-induced thrombin generation
suggests that tissue factor is involved in the pathogenesis
of DIC [29,30]. Although no acquired or deficiency or
functional defect of TFPI has been identified in patients
with DIC, there is evidence that the inhibitor does not reg-
ulate tissue factor activity sufficiently in such patients[30].
As regards impaired fibrinolysis, experimental models of
bacteremia and endotoxemia are characterized by rapidly
increasing fibrinolytic activity, most probably due to the
release of plasminogen activators from endothelial cells.
However, this initialhyperfibrinolytic response is fol-
lowed by an equally rapid suppression of fibrinolytic
activity, due to the increase in plasma levels of plasmino-
gen activator inhibitor type 1 (PAI-1) [31-33]. The impor-
tance of PAI-1 in the pathogenesis of DIC is further
demonstrated by the fact that a functional mutation in the
PAI-1 gene, the 4G/5G polymorphism, which causes
increased plasma levels of PAI-1, was linked to a worse
clinical outcome in patients with meningococcal septi-
cemia [34].
Finally, another important mechanism in the pathogene-
sis of DIC is the parallel and concomitant activation of the
inflammatory cascade mediated by activated coagulation
proteins, which in turn can stimulate endothelial cells to
synthesize pro-inflammatory cytokines. In fact, while
cytokines and inflammatory mediators can induce coagu-
lation, thrombin and other serine proteasesinteract with
protease-activated receptors on cell surfaces to promote
further activation and additional inflammation [35]. Fur-
thermore, since activated protein C has an anti-inflamma-
tory effect through its inhibition of endotoxin-induced
production of TNF-α, IL-1β, IL-6 and IL-8 by cultured
monocytes/macrophages, depression of the protein C sys-
tem may result in a pro-inflammatory state [36].
Thus, inflammatory and coagulation pathways interact
with each other in a vicious circle which amplifies the
Table 1: Clinical conditions associated with disseminated intravascular coagulation.
Condition Causes
Sepsis/severe infections Gram-positive bacteria, Gram-negative bacteria, spirochetes, rickettsiae, 
protozoa, fungi, viruses
Trauma Polytrauma, neurotrauma, fat embolism, burns
Malignancy Solid tumors, myeloproliferative/lymphoproliferative malignancies
Obstetric complications Amniotic fluid embolism, abruptio placentae, placenta previa, retained 
dead fetus syndrome
Vascular disorders Large vascular aneurysms, Kasabach-Merritt syndrome
Organ destruction Severe pancreatitis, severe hepatic failure
Toxic reactions Snake bites, recreational drugs
Immunologic reactions Hemolytic transfusion reaction, transplant rejectionPage 2 of 9
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systemic coagulation [37]. Table 2  summarizes the most
important mechanisms in the pathogenesis of DIC in sep-
sis.
However, there is evidence that various events, including
the release of tissue material (fat, phospholipids, cellular
enzymes) into the circulation, hemolysis and endothelial
damage may promote the systemic activation of coagula-
tion in severe trauma and burns through a mechanism
similar to that observed in septic patients (i.e., systemic
activation of cytokines)[14,15]. Nevertheless, there may
also be specific variations in the pathogenesis if DIC due
to different underlying disorders. For example, in some
patients with cancer the initiation of coagulation activa-
tion is not only due to tissue factor expression on the sur-
face of the malignant cells but in this case also involves a
specific cancer procoagulant, a cysteine protease with fac-
tor X activating properties[38]. Patients with acute promy-
elocytic leukemia have a peculiar form of DIC
characterized by a severe hyperfibrinolytic state associated
with systemic activation of coagulation[17].
Diagnosis of DIC
The most common clinical manifestations of DIC are
bleeding, thrombosis or both, often resulting in dysfunc-
tion of one or more organs [39,40]. A schematic represen-
tation of the clinical manifestations of coagulation
abnormalities in DIC is presented in Figure 1. Since no
single laboratory test or set of tests is sensitive or specific
enough to allow a definite diagnosis of DIC, in most cases
the diagnosis is based on the combination of results of
laboratory investigations in a patient with a clinical con-
dition known to be associated with DIC [2,8]. The classi-
cal characteristic laboratory findings include prolonged
clotting times (prothrombin time, activated partial
thromboplastin time, thrombin time), increased levels of
fibrin-related markers (fibrin degradation products [FDP],
D-dimers), low platelet count and fibrinogen levels and
low plasma levels of coagulation factors (such as factors V
and VII) and coagulation inhibitors (such as anti-
thrombin and protein C) [7,41]. However, the sensitivity
of plasma fibrinogen levels for the diagnosis of DIC is
low, since fibrinogen acts as an acute-phase reactant and
its levels are often within the normal range for a long
period of time. Thus, hypofibrinogenemia is frequently
detected only in very severe cases of DIC [2,4]. On the
other hand, FDP and D-dimer levels have a low specificity
since many other conditions, such as trauma, recent sur-
gery, inflammation or venous thromboembolism, are
associated with elevated levels of these fibrin-related
markers. Other, more specialized and useful tests, not
available in all laboratories, include the measurement of
soluble fibrin and assays of thrombin generation, such as
those to detect prothrombin activation fragments F1+2 or
thrombin-antithrombin complexes [42,43]. However,
serial coagulation tests may bemore helpful than single
laboratory results in establishing the diagnosis of DIC. A
scoring system for the diagnosis of DIC, developed from a
previously described set of diagnostic criteria [44], has
been proposed by the Scientific Subcommittee on DIC of
the International Society on Thrombosis and Haemostasis
(ISTH) [45,46]. This system consists of a five-step diag-
nostic algorithm (see also Figure 2), in which a specific
score, reflecting the severity of the abnormality found, is
given to each of the following laboratory tests: platelet
count (>100 × 109/L = 0; <100 × 109/L = 1, <50 × 109/L =
2), elevated fibrin-related markers (e.g. soluble fibrin
monomers/fibrin degradation products) (no increase = 0;
moderate increase = 2; strong increase = 3), prolonged
prothrombin time (< 3 sec. = 0; > 3 sec. but < 6 sec. = 1; >
6 sec. = 2), fibrinogen level (> 1 g/L = 0; < 1 g/L = 1). A
total score of 5 or more is considered to be compatible
with DIC. According to recent observations, the sensitivity
and specificity of this scoring system are high (more than
90%) [46]. However, an essential condition for the use of
this algorithm is the presence of an underlying disorder
known to be associated with DIC [8]. Finally, a scoring
system for diagnosing non-overt DIC has recently been
proposed by the ISTH Scientific Subcommittee and vali-
Table 2: Pathogenesis of disseminated intravascular coagulation in sepsis.
Mechanism Pathophysiology
1) Increased thrombin generation Mediated predominantlyby tissue factor/factor VIIa pathway
2) Impaired function of physiological anticoagulant pathway
a) Reduction of antithrombin levels The result of a combination of increased consumption, enzyme 
degradation, impaired liver synthesis and vascular leakage
b) Depression of protein C system The result of a combination of increased consumption, impaired liver 
synthesis, vascular leakage and down- regulation of thrombomodulin
c) Insufficienttissue factor pathway inhibitor (TFPI)
3) Impaired fibrinolysis Mediated by release of plasminogen activators from endothelial cells 
immediately followed by an increase in the plasma levels of plasminogen 
activator inhibitor type 1 (PAI-1)
4) Activation of inflammatory pathway Mediated by activated coagulation proteins and by depression of the 
protein C systemPage 3 of 9
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ity and prognostic relevance[47].
Treatment of DIC
The heterogeneity of the underlying disorders and of the
clinical presentations makes the therapeutic approach to
DIC particularly difficult [2,48]. Thus, the management of
DIC is based on the treatment of the underlying disease,
supportive and replacement therapies and the control of
coagulation mechanisms. The recent understanding of
important pathogenetic mechanisms that may lead to
DIC has resulted in novel preventive and therapeutic
approaches to patients with DIC [49]. However, in spite of
this progress, the therapeutic decisions are still controver-
sial and should be individualized on the basis of the
nature of DIC and the severity of the clinical symptoms
[50-52]. The treatment for DIC include replacement ther-
apy, anticoagulants, restoration of anticoagulant path-
ways and other agents [1,2,8]. Most of the clinical studies
reported in the next paragraphs were conducted in
patients with severe sepsis [53,54], a condition which usu-
ally leads to generalized activation of coagulation and
thus represents an interesting model for the development
of new treatment modalities. Table 3 summarizes the
treatment modalities for DIC.
a) Replacement therapy
The aim of replacement therapy in DIC is to replace the
deficiency due to the consumptionof platelets, coagula-
tion factors and inhibitors in order to prevent or arrest the
hemorrhagic episodes [39]. Platelet concentrates and
fresh frozen plasma (FFP) were, in the past, used very cau-
tiously because of the fear that they might "feed the fire"
and worsen thrombosis in patients with active DIC. How-
ever, this fear was not confirmed by clinical practice and
nowadays replacement therapy is a mainstay of the treat-
ment of patients with significant bleeding and coagula-
tion parameters compatible with DIC. Transfusion of
platelet concentrates at 1–2 U/10 Kg body weight should
be considered when the platelet count is less than 20 ×
109/L or if there is major bleeding and the platelet count
is less than 50 × 109/L. When there is significant DIC-asso-
ciated bleeding and fibrinogen levels are below 100 mg/
dL, the use of FFP, at a dose of 15–20 mL/Kg, is justified.
Alternatively, fibrinogen concentrates (total dose 2–3 g)
or cryoprecipitates (1 U/10 Kg body weight) may be
administered. However, FFP should be preferred to spe-
cific coagulation factor concentrates since the former con-
tains all coagulation factors and inhibitors deficient
during active DIC and lacks traces of activated coagulation
factors, which may instead contaminate the concentrates
and exacerbate the coagulation disorder.
b) Anticoagulants
The role of heparin in the treatment of DIC remains con-
troversial [55-62]. In fact, although from a theoretical
Clinical manifestations of coagulation abnormalities in dis-sem n ted intrav scular coagulationFigure 1
Clinical manifestations of coagulation abnormalities in dis-
seminated intravascular coagulation.
Table 3: Treatment modalities for disseminated intravascular coagulation.
1) Replacement therapy - Fresh-frozen plasma
2) Anticoagulants - Unfractionated and low-molecular-weight heparin
- Danaparoid sodium
- Recombinant hirudin
- Recombinant tissue factor pathway inhibitor
- Recombinant nematode anticoagulant protein c2
3) Restoration of anticoagulant pathways - Antithrombin
- Recombinant human activated protein C




- Monoclonal antibodies against TNF and CD14Page 4 of 9
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should be of benefit in patients with active DIC [55], the
clinical studies carried out so far have not been conclusive
and indeed have often yielded contradictory results [56].
However, on the basis of the few data available in the lit-
erature, heparin treatment is probably useful in patients
with acute DIC and predominant thromboembolism,
such as those with purpura fulminans [2,56]. The use of
heparin in chronic DIC is better established and it has
been successfully employed in patients with chronic DIC
associated with those diseases in which recurrent throm-
bosis predominates, such as solid tumors, hemangiomas,
and dead fetus syndrome [61]. The role of heparin in the
treatment of DIC associated with acute promyelocytic
leukemia (APL) is another controversy, since some
authors support its use whereas other studies failed to
demonstrate its efficacy [57-59]. However, the use of
heparin in this setting has declined in the last few years
thanks to the introduction of all-trans retinoic acid ther-
apy which has led to the reduction of APL-associated coag-
ulopathy. Heparin is usually given at relatively low doses
(5–10 U/Kg of body weight per hour) by continuous
intravenous infusion and may be switched to subcutane-
ous injection for long-term outpatient therapy (i.e. for
those patients with chronic DIC associated with solid
tumors). Alternatively, low-molecular-weight heparin
may be used, as supported by the positive results in both
experimental and clinical DIC studies [60-63].
Experimental and clinical studies have also shown the
potential role of danaparoid sodium, a low molecular
weight heparinoid, in the treatment of DIC [64-66].
A newer anticoagulant agent with direct thombin inhibi-
tory activity, recombinant hirudin (r-hirudin) [67,68],
was recently shown to be effective in treating DIC in ani-
mal studies, although a study of the effect of this
thrombin inhibitor in a sheep model of lethal endotox-
emia showed no benefit [69]. Preliminary experimental
human studies proved that this drug attenuated endo-
toxin-induced coagulation activation [70].
Since activation of the coagulation cascade during DIC
occurs predominantlythrough the extrinsic pathway, the-
oretically the inhibition of tissue factor should block
endotoxin-associated thrombin generation [71]. In vivo
experiments in baboon models of lethal DIC showed that
TFPI is a potent inhibitor of sepsis-related mortality [72].
De Jonge and colleagues [29] first demonstrated in
humans that recombinant TFPI dose-dependently inhib-
its coagulation activation during endotoxemia. Recom-
binant TFPI was evaluated in a phase II randomized trial
in patients with severe sepsis [73]. Although the study did
not have the statistical power to demonstrate a survival
benefit, it did show a trend toward a reduction in 28-day
all-cause mortality together with an improvement in
organ dysfunction in the group of patients treated with
the recombinant TFPI. No evidence of a survival advan-
tage was observed in patients with severe sepsis who
received recombinant TFPI in a recent phase III large clin-
ical trial[74].
Inhibition of the tissue factor/factor VIIa pathway is an
another strategy that has been explored. Moons and col-
leagues demonstrated the efficacy of recombinant nema-
tode anticoagulant protein c2 (NaPc2), a potent and
specific inhibitor of the ternary complex between tissue
factor/factor VIIa and factor Xa, in inhibiting coagulation
activation in a primate model of sepsis [75]. Other
authors have experimented with anti-tissue factor/factor
VIIa antibodies in animal models with promising results
[23].
c) Restoration of anticoagulant pathways
Since patients with active DIC have an acquired deficiency
of coagulation inhibitors, restoration of the physiologic
anticoagulation pathways seems to be an appropriate aim
of the treatment of DIC [76]. Considering that anti-
thrombin (AT) is the primary inhibitor of circulating
thrombin, its use in DIC is certainly rational [77]. Recent
studies in animals and humans with severe sepsis have
demonstrated that antithrombin also has anti-inflamma-
tory properties (reduction of C-reactive protein and IL-6
levels), which may further justify its utilization during
DIC [78,79]. The administration of antithrombin concen-
trates infused at supraphysiologic concentrations was
shown to reduce sepsis-related mortality in animal mod-
els [80]. Several small clinical trials have been conducted
in humans, mostly in patients with sepsis-related DIC,
and have shown beneficial effects in terms of improve-
ment of coagulation parameters and organ function
[81,82]. An Italian multicenter, randomized, double-
blind study conducted in 1998 by Baudo et al. [83], eval-
uating the role of antithrombin in patients with sepsis or
post-surgical complications, showed a net beneficial effect
on survival in those patients receiving the concentrate.
These findings were confirmed in 1999 by Levi et al. in
their meta-analysis of all so far published human clinical
trials of antithrombin treatment of DIC [3]. By contrast, a
large randomized, controlled multicenter trial of supra-
physiologic doses of AT concentrates conducted in 2144
patients with sepsis and DIC did not show a beneficial
effect of antithrombin treatment [84]. However, a retro-
spective analysis of the same trial showed that the sub-
group of patients who did not receive concomitant
heparin had a potential benefit from antithrombin III in
terms of mortality reduction[85].
Based on the fact that the protein C system is impaired
during DIC some authors have investigated the therapeu-Page 5 of 9
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patients with DIC [86-98]. The infusion of activated pro-
tein C (APC) concentrates was shown to prevent DIC and
mortality in an animal model of sepsis [99]. A study con-
ducted in 1998 on patients with severe sepsis suggested a
trend toward improved survival in the group treated with
APC [88]. In a dose-ranging clinical trial, 131 patients
with sepsis received recombinant human APC by contin-
uous infusion at doses ranging from 12µg/Kg/hour to 30
µg/Kg/hour or placebo [89]. A 40 percent reduction in
mortality was observed in those patients who received the
higher doses of activated protein C. Similarly, another
recent multicenter clinical trial [90] determined that treat-
ment with recombinant human APC, given intravenously
at a dose of 24 µg/Kg of body weight per hour, signifi-
cantly reduced mortality in patients with severe sepsis, in
spite of a higher rate of serious bleeding in the APC-
treated group. A double-blind randomized trial compared
the safety and efficacy of APC and unfractionated heparin
in the treatment of DIC and concluded that the former
improved DIC, and finally the survival, more efficiently
than did heparin [91]. The recently published results of
the trial conducted by the Human Recombinant Activated
Protein C Worldwide Evaluation in Sepsis (PROWESS)
Study Group showed a significant reduction in 28-day
mortality and a quicker resolution of organ dysfunction in
the group of patients with severe sepsis treated with APC
[92,93]. These results were confirmed by the ENHANCE
trial which also suggested that recombinant APC might be
more effective is therapy is started earlier [94]. By contrast,
a very recent trial on 2640 patients with severe sepsis and
a low risk of death (defined by an Acute Physiology and
Chronic Health Evaluation [APACHE II] score <25 or sin-
gle organ failure) did not find a statistically significant dif-
ference in 28-day mortality rate between the placebo and
APC-treated groups[95], suggesting that APC is of benefit
only in patients at high risk of death from sepsis.Ongoing
studies are focusing on the concomitant use of heparin in
patients with DIC who receive activated protein C [8].
d) Other agents
Recombinant factor VII activated (rFVIIa) may be used in
patients with severe bleeding who are not responsive to
other treatment options. Bolus doses of 60–120 µg/Kg,
possibly repeated after 2–6 hours, have been found to be
effective in controlling refractory hemorrhagic episodes
associated with DIC [100,101]. Antifibrinolytic agents,
such as epsilon-aminocaproic acid or tranexamic acid,
given intravenously at a dose of 10–15 mg/Kg/h, are occa-
sionally used in patients resistant to replacement therapy
who are bleeding profusely or in patients with disease
states associated with intense fibrinolysis (prostate cancer,
Kasabach-Merrit syndrome, acute promyelocytic leuke-
mia) [102]. However, since these agents are very effective
in blocking fibrinolysis, they should not be administered
unless heparin has been previously infused in order to
block the prothrombotic component of DIC. The use of
these drugs in APL has declined in the last few years, given
the efficacy of all-trans-retinoic-acid in preventing the
majority of the hemorrhagic complications of this malig-
nancy [8].
The advances in the understanding of the pathophysiol-
ogy of DIC have resulted in novel preventive and thera-
peutic approaches to this disease. Based on the fact that
tissue inflammation is a fundamental mechanism in DIC
associated with sepsis or major trauma, some researchers
have successfully employed the combined blockade of
leukocyte/platelet adhesion and coagulation in a murine
model by using antiselectin antibodies and heparin and
have suggested the potential clinical use of such a strategy
Five-step algorithm for the diagnosis of disseminated intra-vascular coagulationigure 2
Five-step algorithm for the diagnosis of disseminated intra-
vascular coagulation.
Step 1. Risk assessment 
Does the patient have un underlying disorder known to be associated with DIC? 
       NO          YES 
  
  STOP   STEP 2. Check coagulation tests 
       Platelet count, PT, fibrinogen, soluble fibrin monomers, FDPs 
STEP 3. Score global coagulation test results 
- Platelet count (x10
9
/L): >100 = 0; <100 = 1; <50 
= 2 
- PT (sec.): <3 = 0; >3 but >6 = 1; >6 = 2 
- Fibrinogen (g/L): >1 = 0; <1 = 1 
- Fibrin-related markers: no increase = 0; 
moderate increase = 2; strong increase = 3 
STEP 4. Calculate score 
 STEP.5 If ≥ 5   STEP 5. If < 5 
Compatible with overt DIC          Suggestive of non- 
                overt DIC 
Repeat scoring daily Repeat after 1-2 days Page 6 of 9
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demonstrated that the administration of recombinant IL-
10, an anti-inflammatory cytokine which may modulate
the activation of coagulation, completely abrogated endo-
toxin-induced effects on coagulation in humans [104]. By
contrast, the use of monoclonal antibodies against tumor
necrosis factor has shown disappointing or at best modest
results in septic patients[105-107]. More recently, Branger
and colleagues[108]found that an inhibitor of p38
mitogen-activated protein kinase (MAPK), an important
component of intracellular signaling cascades that medi-
ate the inflammatory response to infectious and non-
infectious stimuli, attenuated the activation of coagula-
tion, fibrinolysis and endothelial cells during human
endotoxemia. Finally, although studies using antibodies
against the receptor for bacterial endotoxins (CD14) pro-
duced positive results[109], other studies using endotoxin
antibodies failed to improve outcome[110,111].
Conclusion
Disseminated intravascular coagulation is a syndrome
characterized by systemic intravascular activation of coag-
ulation leading to bleeding (due to depletion of platelets
and coagulation factors) and thrombosis(due to wide-
spread deposition of fibrin in the circulation).
The diagnosis of DIC is usually made by a combination of
routinely available laboratory tests, using a validated diag-
nostic algorithm.
In recent years, the mechanisms involved in pathological
microvascular fibrin deposition in DIC have become pro-
gressively clear, resulting in novel preventive and thera-
peutic approaches to patients with DIC.
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